Hikma Pharmaceuticals negotiated rights to register, market, and distribute GP Pharm’s lead androgen deprivation therapy Lutrate® 1 month (leuprolide acetate 3.75 mg) in 23 countries in the Middle East and North Africa (MENA) region. The new deal will also position Hikma as GP Pharm’s preferred partner for its pipeline of oncology products in the MENA region.
The prostate cancer drug Lutrate is currently approved in the EU, and regulatory filings in the U.S. and other countries are projected for the near future. GP Pharm is in addition developing 3-month and 6-month depot formulations.
With expertise in drug delivery systems including microspheres and liposomes, Spanish biopharma GP Pharm is focused on the development, manufacture, and commercialization of injectable drugs for urology and oncology indications. Lutrate 1 month is the first drug developed by GP Pharm right through from research through to market launch and commercialization, making the firm one of the only Spanish biotechs to have achieved its own product launch.